
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2351212/publications.pdf Version: 2024-02-01



Марсо Циссни

#	Article	IF	CITATIONS
1	OUP accepted manuscript. Interactive Cardiovascular and Thoracic Surgery, 2022, , .	1.1	1
2	Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers. Diagnostics, 2022, 12, 674.	2.6	2
3	The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors. Journal of Thoracic Oncology, 2022, 17, 838-851.	1.1	12
4	A Delphi Consensus report from the "Prolonged Air Leak: A Survey" study group on prevention and management of postoperative air leaks after minimally invasive anatomical resections. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	5
5	Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis. European Thyroid Journal, 2021, 10, 237-247.	2.4	7
6	Thymomaâ€associated myasthenia gravis : Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. Thoracic Cancer, 2021, 12, 106-113.	1.9	13
7	Prognostic impact of lung adenocarcinoma second predominant pattern from a large European database. Journal of Surgical Oncology, 2021, 123, 560-569.	1.7	9
8	OUP accepted manuscript. European Journal of Cardio-thoracic Surgery, 2021, 60, 1210-1211.	1.4	0
9	Prognostic role of standard uptake value according to pathologic features of lung adenocarcinoma. Tumori, 2021, , 030089162110185.	1.1	1
10	Surgery for thymomas: is less worthwhile? A clear answer from the European experience. European Journal of Cardio-thoracic Surgery, 2021, 60, 888-889.	1.4	0
11	Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma. Annals of Translational Medicine, 2021, 9, 960-960.	1.7	11
12	Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results. Annals of Translational Medicine, 2021, 9, 957-957.	1.7	8
13	The International Thymic Malignancy Interest Group Classification of Thymoma Recurrence: Survival Analysis and Perspectives. Journal of Thoracic Oncology, 2021, 16, 1936-1945.	1.1	2
14	Prognostic factors for survival in advanced thymomas: The role of the number of involved structures. Journal of Surgical Oncology, 2021, 124, 858-866.	1.7	5
15	Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: The Forefront of Surgery-Based Multimodality Treatment. Journal of Clinical Medicine, 2021, 10, 3801.	2.4	8
16	Thymectomy in Myasthenic Patients With Thymoma: Killing Two Birds With One Stone. Annals of Thoracic Surgery, 2021, 112, 1782-1789.	1.3	16
17	Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients. Journal of Thoracic Disease, 2021, 13, 6373-6380.	1.4	1
18	Expression of miRNA-25 in young and old lung adenocarcinoma. Journal of Research in Medical Sciences, 2021, 26, 132.	0.9	2

#	Article	IF	CITATIONS
19	Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma. Pathology and Oncology Research, 2020, 26, 1089-1096.	1.9	2
20	The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors. Journal of Thoracic Oncology, 2020, 15, 436-447.	1.1	46
21	Laryngotracheal resection for a post-tracheotomy stenosis in a patient with coronavirus disease 2019 (COVID-19). JTCVS Techniques, 2020, 4, 360-364.	0.4	14
22	Investigation of MLH1, MGMT, CDKN2A, and RASSF1A Gene Methylation in Thymomas From Patients With Myasthenia Gravis. Frontiers in Molecular Neuroscience, 2020, 13, 567676.	2.9	3
23	Investigation of GHSR methylation levels in thymomas from patients with Myasthenia Gravis. Gene, 2020, 752, 144774.	2.2	6
24	Surgical treatment of pleural recurrence of thymoma: is hyperthermic intrathoracic chemotherapy worthwhile?. Interactive Cardiovascular and Thoracic Surgery, 2020, 30, 765-772.	1.1	18
25	A gene‑expression‑based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations. Oncology Letters, 2020, 19, 1060-1065.	1.8	3
26	Extracorporeal membrane oxygenation in traumatic tracheal injuries: a bold life-saving option. Journal of Thoracic Disease, 2019, 11, 2660-2663.	1.4	8
27	Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experience. Lung Cancer, 2019, 138, 27-34.	2.0	10
28	Nerve-Sparing Surgery in Advanced Stage Thymomas. Annals of Thoracic Surgery, 2019, 107, 878-884.	1.3	12
29	Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas. Scientific Reports, 2019, 9, 3536.	3.3	11
30	Is left upper lobectomy always worthwhile for early stage lung cancer? A comparison between left upper lobectomy, trisegmentectomy, and lingulectomy. Journal of Surgical Oncology, 2018, 117, 618-624.	1.7	13
31	The thymidylate synthase enhancer region (TSER) polymorphism increases the risk of thymic lymphoid hyperplasia in patients with Myasthenia Gravis. Gene, 2018, 642, 376-380.	2.2	4
32	The role of intracavitary therapies in the treatment of malignant pleural mesothelioma. Journal of Thoracic Disease, 2018, 10, S293-S297.	1.4	24
33	Imaging of malignant pleural mesothelioma: it is possible a screening or early diagnosis program?—a systematic review about the use of screening programs in a population of asbestos exposed workers. Journal of Thoracic Disease, 2018, 10, S262-S268.	1.4	11
34	Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. Biomedical Reports, 2018, 9, 198-205.	2.0	2
35	Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Scientific Reports, 2017, 7, 3140.	3.3	55
36	Prognostic role of TPL2 in early-stage non-small cell lung cancer. Molecular Medicine Reports, 2017, 15, 3451-3458.	2.4	3

#	Article	IF	CITATIONS
37	Single lymph node metastasis 10Âyears after radical resection of a thymoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, e11-e13.	0.8	1
38	Serum Mesothelin, Osteopontin and Vimentin: Useful Markers for Clinical Monitoring of Malignant Pleural Mesothelioma. International Journal of Biological Markers, 2017, 32, 126-131.	1.8	30
39	Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. Cancer Cell International, 2017, 17, 105.	4.1	38
40	Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis. Oncotarget, 2017, 8, 2758-2770.	1.8	26
41	Gene-Specific Methylation Analysis in Thymomas of Patients with Myasthenia Gravis. International Journal of Molecular Sciences, 2016, 17, 2121.	4.1	18
42	Chest wall resection for mesothelioma recurrence after surgery. Asian Cardiovascular and Thoracic Annals, 2016, 24, 893-895.	0.5	4
43	Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group. European Journal of Cardio-thoracic Surgery, 2016, 50, 766-771.	1.4	52
44	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncology Reports, 2016, 36, 1166-1172.	2.6	15
45	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1204-1223.	1.1	530
46	Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors: Long-term results from a multicentre analysis of 108 cases. Lung Cancer, 2016, 93, 88-94.	2.0	7
47	The IASLC Lung Cancer Staging Project: Proposals forÂRevision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 39-51.	1.1	3,162
48	Surgical treatment of recurrent thymoma: is it worthwhile?. European Journal of Cardio-thoracic Surgery, 2016, 49, 327-332.	1.4	36
49	Pleural recurrence of thymoma: surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy: Table 1:. European Journal of Cardio-thoracic Surgery, 2016, 49, 321-326.	1.4	37
50	Endoscopic thymectomy: a neurologist's perspective. Annals of Cardiothoracic Surgery, 2016, 5, 38-44.	1.7	7
51	Transcollation® technique in the thoracoscopic treatment of primary spontaneous pneumothorax. Interactive Cardiovascular and Thoracic Surgery, 2015, 20, 445-448.	1.1	9
52	P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value. Oncology Letters, 2015, 9, 449-453.	1.8	24
53	Does the World Health Organization histological classification predict outcomes after thymomectomy? Results of a multicentre study on 750 patients. European Journal of Cardio-thoracic Surgery, 2015, 48, 48-54.	1.4	25
54	Does myasthenia gravis influence overall survival and cumulative incidence of recurrence in thymoma patients? A Retrospective clinicopathological multicentre analysis on 797 patients. Lung Cancer, 2015, 88, 338-343.	2.0	33

#	Article	IF	CITATIONS
55	Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer. European Respiratory Journal, 2015, 45, 1089-1097.	6.7	26
56	Thymic carcinoma outcomes and prognosis: Results of an international analysis. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 95-101.e2.	0.8	190
57	Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 103-109.e2.	0.8	96
58	Expression status of candidate genes in mesothelioma tissues and cell lines. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 771, 6-12.	1.0	25
59	Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors. Journal of Thoracic Oncology, 2014, 9, 1573-1578.	1.1	106
60	<i>ALK</i> Rearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. Archives of Pathology and Laboratory Medicine, 2014, 138, 1449-1458.	2.5	93
61	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the N and M Components for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. Journal of Thoracic Oncology, 2014, 9, S81-S87.	1.1	104
62	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. Journal of Thoracic Oncology, 2014, 9, S65-S72.	1.1	352
63	The ITMIC/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors. Journal of Thoracic Oncology, 2014, 9, S88-S96.	1.1	119
64	A Common Polymorphism Within MSLN Affects miR-611 Binding Site and Soluble Mesothelin Levels in Healthy People. Journal of Thoracic Oncology, 2014, 9, 1662-1668.	1.1	25
65	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. Journal of Thoracic Oncology, 2014, 9, S73-S80.	1.1	155
66	Robotic lobectomy for lung cancer: evolution in technique and technology. European Journal of Cardio-thoracic Surgery, 2014, 46, 626-631.	1.4	39
67	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature Genetics, 2014, 46, 844-849.	21.4	208
68	Historical perspectives: The evolution of the thymic epithelial tumors staging system. Lung Cancer, 2014, 83, 126-132.	2.0	59
69	Extended Versus Standard Thymectomy for Myasthenia Gravis. Difficult Decisions in Surgery: an Evidence-based Approach, 2014, , 677-687.	0.0	1
70	KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. Lung Cancer, 2013, 81, 377-381.	2.0	8
71	EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: A case report. Lung Cancer, 2013, 81, 297-301.	2.0	10
72	Let-7g and miR-21 expression in non-small cell lung cancer: Correlation with clinicopathological and molecular features. International Journal of Oncology, 2013, 43, 765-774.	3.3	53

#	Article	IF	CITATIONS
73	The IASLC/ITMIG Thymic Malignancies Staging Project: Development of a Stage Classification for Thymic Malignancies. Journal of Thoracic Oncology, 2013, 8, 1467-1473.	1.1	76
74	Differential Expression of Extracellular Matrix Constituents and Cell Adhesion Molecules between Malignant Pleural Mesothelioma and Mesothelial Hyperplasia. Journal of Thoracic Oncology, 2013, 8, 1389-1395.	1.1	25
75	Association of the DNMT3B -579G>T Polymorphism with Risk of Thymomas in Patients with Myasthenia Gravis. PLoS ONE, 2013, 8, e80846.	2.5	14
76	Ten-year experience of mediastinal robotic surgery in a single referral centre. European Journal of Cardio-thoracic Surgery, 2012, 41, 847-851.	1.4	61
77	Robotic extended thymectomy for early-stage thymomas. European Journal of Cardio-thoracic Surgery, 2012, 41, e43-e47.	1.4	51
78	Thymectomy for thymoma and myasthenia gravis. A survey of current surgical practice in thymic disease amongst EACTS members. Interactive Cardiovascular and Thoracic Surgery, 2012, 14, 765-770.	1.1	8
79	PTPN22 and myasthenia gravis: Replication in an Italian population and meta-analysis of literature data. Neuromuscular Disorders, 2012, 22, 131-138.	0.6	20
80	Radio-guided thoracoscopic surgery (RGTS) of small pulmonary nodules. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 914-919.	2.4	59
81	Primary Neuroendocrine Tumors of the Thymus: A Multicenter Experience of 35 Patients. Annals of Thoracic Surgery, 2012, 94, 241-246.	1.3	59
82	Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2011, 6, 1587-1593.	1.1	57
83	Surgical treatment of non-small cell lung cancer in octogenarians. Interactive Cardiovascular and Thoracic Surgery, 2011, 12, 749-753.	1.1	50
84	Surgical treatment of stage III thymic tumors: a multi-institutional review from four Italian centersâ~†. European Journal of Cardio-thoracic Surgery, 2011, 39, e1-e7.	1.4	33
85	Surgical Treatment of Recurrent Thymomas. Journal of Thoracic Oncology, 2010, 5, S348-S351.	1.1	34
86	Polymer self-locking clips for vascular control during minimally invasive pulmonary lobectomies. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 1345-1346.e1.	0.8	7
87	Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?â~†. Interactive Cardiovascular and Thoracic Surgery, 2010, 10, 572-576.	1.1	8
88	Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13040-13045.	7.1	123
89	Association of thymoma and myasthenia gravis: oncological and neurological results of the surgical treatmentâ~†. European Journal of Cardio-thoracic Surgery, 2009, 35, 812-816.	1.4	61
90	Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study. Oncology Reports, 2009, 22, 683-91.	2.6	25

#	Article	IF	CITATIONS
91	Management of pleural recurrence after curative resection of thymoma. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 1185-1189.	0.8	79
92	Laser capture microdissection: A tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. International Journal of Molecular Medicine, 2009, 24, 473-9.	4.0	3
93	Tryptase Mast Cells in Malignant Pleural Mesothelioma as an Independent Favorable Prognostic Factor. Journal of Thoracic Oncology, 2009, 4, 348-354.	1.1	37
94	Different estrogen receptor β expression in distinct histologic subtypes of lung adenocarcinoma. Human Pathology, 2008, 39, 1465-1473.	2.0	40
95	Effect of the p53 Codon 72 and Intron 3Polymorphisms on Non-Small Cell Lung Cancer (NSCLC) Prognosis. Cancer Investigation, 2008, 26, 168-172.	1.3	20
96	Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction. European Journal of Cardio-thoracic Surgery, 2008, 34, 181-186.	1.4	41
97	Surgical treatment of pleural recurrence from thymoma. European Journal of Cardio-thoracic Surgery, 2008, 33, 707-711.	1.4	30
98	Reply to Heyman and Van Schil. European Journal of Cardio-thoracic Surgery, 2008, 34, 708-708.	1.4	0
99	Radioguided Surgery of Solitary Pulmonary Nodules. , 2008, , 262-268.		6
100	Conventional Techniques: Median Sternotomy. , 2008, , 157-160.		0
101	A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage Il–III malignant pleural mesotheliomaâ~†. European Journal of Cardio-thoracic Surgery, 2007, 31, 529-534.	1.4	38
102	WWOX Expression in Different Histologic Types and Subtypes of Non–Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 884-891.	7.0	58
103	Four-Modality Therapy in Malignant Pleural Mesothelioma: A Phase II Study. Journal of Thoracic Oncology, 2007, 2, 237-242.	1.1	30
104	CDC25B: relationship with angiogenesis and prognosis in non–small cell lung carcinoma. Human Pathology, 2007, 38, 1563-1568.	2.0	11
105	Sleeve and wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the bronchial airway. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 373-377.	0.8	47
106	Four thymus-related syndromes in a case of invasive thymoma. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 1376-1378.	0.8	4
107	Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up. Journal of Thoracic Oncology, 2006, 1, 308-313.	1.1	35
108	Percutaneous radiofrequency ablation of lung tumours: results in the mid-termâ~†. European Journal of Cardio-thoracic Surgery, 2006, 30, 177-183.	1.4	121

#	Article	IF	CITATIONS
109	Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up. Journal of Thoracic Oncology, 2006, 1, 308-313.	1.1	60
110	Neoadjuvant chemotherapy for stage III and IVA thymomas: a single-institution experience with a long follow-up. Journal of Thoracic Oncology, 2006, 1, 308-13.	1.1	20
111	Osteopontin Expression and Prognostic Significance in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 6459-6465.	7.0	98
112	Metachronous adrenal masses in resected non-small cell lung cancer patients: therapeutic implications of laparoscopic adrenalectomy. European Journal of Cardio-thoracic Surgery, 2005, 27, 753-756.	1.4	45
113	Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. European Journal of Cancer, 2005, 41, 2828-2835.	2.8	45
114	Advanced Stage Thymomas and Thymic Carcinomas: Results of Multimodality Treatments. Annals of Thoracic Surgery, 2005, 79, 1840-1844.	1.3	133
115	Interleukin-8 in non-small cell lung carcinoma: Relation with angiogenic pattern and p53 alterations. Lung Cancer, 2005, 50, 309-317.	2.0	31
116	Expression and Mutational Status of c-kit in Small-Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 4101-4108.	7.0	87
117	Massive pneumoencephalus of late onset after an en bloc resection for lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 1836-1838.	0.8	6
118	A Reappraisal of the Indications for Laparoscopic Treatment of Adrenal Metastases. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2004, 14, 139-145.	1.0	16
119	Applications of tissue microarray technology in immunohistochemistry: A study on c-kit expression in small cell lung cancer. Human Pathology, 2004, 35, 1347-1352.	2.0	11
120	Thymectomy in ocular myasthenia gravis. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 740-741.	0.8	3
121	Small cell lung carcinoma (SCLC): the angiogenic phenomenon. European Journal of Cardio-thoracic Surgery, 2002, 21, 1105-1110.	1.4	124
122	Focus on cosmesis in thymectomy for myasthenia gravis: Reply. Annals of Thoracic Surgery, 2001, 72, 1442.	1.3	0
123	Limbic encephalitis associated with thymic cancer: a case report. Journal of Neurology, 2001, 248, 1000-1002.	3.6	10
124	Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. Oncogene, 2001, 20, 6632-6637.	5.9	22
125	Extended thymectomy in myasthenia gravis: a team-work of neurologist, thoracic surgeon and anaesthesist may improve the outcome. European Journal of Cardio-thoracic Surgery, 2001, 19, 570-575.	1.4	34
126	Gamma Probe-Guided Thoracoscopic Surgery of Small Pulmonary Nodules. Tumori, 2000, 86, 364-366.	1.1	16

#	Article	IF	CITATIONS
127	A pilot study of the role of TC-99 radionuclide in localization of pulmonary nodular lesions for thoracoscopic resection✩. European Journal of Cardio-thoracic Surgery, 2000, 18, 17-21.	1.4	146
128	Reversed-T upper mini-sternotomy for extended thymectomy in myasthenic patients. Annals of Thoracic Surgery, 2000, 70, 1423-1424.	1.3	44
129	The utility of polyglactin-910 mesh in the plastic reconstruction of the chest wall after en-bloc resection. European Journal of Surgical Oncology, 1996, 22, 377-380.	1.0	10
130	Resection of single brain metastasis in non-small-cell lung cancer: Prognostic factors. Journal of Thoracic and Cardiovascular Surgery, 1996, 112, 146-153.	0.8	86
131	Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (Stage IIIA-N2): Impact of adjuvant therapies in a subset of patients at high risk of recurrence. , 1996, 78, 409-415.		60
132	Neoangiogenesis: A putative marker of malignancy in non-small-cell-lung-cancer (NSCLC) development. , 1996, 67, 615-619.		32
133	Microvessel count predicts metastatic disease and survival in nonâ€small cell lung cancer. Journal of Pathology, 1995, 177, 57-63.	4.5	166